Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients
Status:
Recruiting
Trial end date:
2022-06-05
Target enrollment:
Participant gender:
Summary
Evaluate the Efficacy and Safety of Sintilimab Combined with Metformin Hydrochloride in
Patients with Advanced Non-small Cell Lung Cancer Refractory to First-Line
Platinum-Containing Chemotherapy
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital